Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 3, Multi-Center, Randomized, Open-Label Study of Vabomere(Meropenem-vaborbactam) Versus Best Available Therapy in Subjects With Selected Serious Infections Due to Carbapenem-Resistant Enterobacteriaceae (CRE)

NCT02168946 is registered in ClinicalTrials.gov with Rempex (a wholly owned subsidiary of Melinta Therapeutics, Inc.) as lead sponsor.

NCT NCT02168946
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02168946 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 3, Multi-Center, Randomized, Open-Label Study of Vabomere(Meropenem-vaborbactam) Versus Best Available Therapy in Subjects With Selected Serious Infections Due to Carbapenem-Resistant Enterobacteriaceae (CRE)
Lead sponsor
Rempex (a wholly owned subsidiary of Melinta Therapeutics, Inc.)
Phase
Phase 3
Overall status
Completed
Start date
July 31, 2014
Completion date
July 21, 2017
Enrollment
77 (actual)
Sites
50

Conditions

As the registry lists them; a condition with its own page is linked.

abdominal infection, acute pyelonephritis, bacteremia, hospital acquired bacterial pneumonia, urinary tract infection complicated, ventilator-associated bacterial pneumonia